Phase I II study of S-1 combined with irinotecan for metastatic advanced gastric cancer

A dose-escalation study of irinotecan (CPT-11) combined with S-1, an oral dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, was performed to determine the maximum-tolerated dose (MTD), recommended dose (RD), dose-limiting toxicities (DLTs), and objective response rate (RR) in advanced gas...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of cancer 2006-04, Vol.94 (8), p.1130-1135
Hauptverfasser:	Inokuchi, M, Yamashita, T, Yamada, H, Kojima, K, Ichikawa, W, Nihei, Z, Kawano, T, Sugihara, K
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Adult Aged Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biomedical and Life Sciences Biomedicine Camptothecin - administration & dosage Camptothecin - adverse effects Camptothecin - analogs & derivatives Cancer Research Clinical Study Disease Progression Dose-Response Relationship, Drug Drug Administration Schedule Drug Combinations Drug Resistance Epidemiology Female Humans Injections, Intravenous Irinotecan Male Maximum Tolerated Dose Middle Aged Molecular Medicine Neoplasm Staging Oncology Oxonic Acid - administration & dosage Oxonic Acid - adverse effects Safety Stomach Neoplasms - drug therapy Survival Rate Tegafur - administration & dosage Tegafur - adverse effects Time Factors Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!